Learn more about our upcoming Galas and Signature Events Learn More
Guest blog post by Ian Michael Crumm, Celebrity Esthetician, Podcast Host, Key Opinion Leader, Melanoma Advocate and 2025 #GetNaked Spokesperson: Some moments stick with yo...
There’s been much buzz about the new Showtime series, “The Big C” and the portrayal of cancer on the show. But what do melanoma patients think about...
Amy Harmon, a reporter for The New York Times spoke with the Melanoma Research Foundation’s executive director, Tim Turnham about the promising results and increased ...
WASHINGTON— For years, researchers in the melanoma field have worked tirelessly against funding shortfalls, a shortage of researchers and the complexities of the dise...
The Melanoma Research Foundation (MRF) was pleased to see Laura Linney’s portrayal of a woman with advanced melanoma honored by the Hollywood Foreign Press Associatio...
Pharmawire recently featured this article on the U.S. Food and Drug Administration’s (FDA) newly released draft guidelines for the co-development of combination thera...
The New York Times' latest installment in their ongoing coverage of melanoma focuses on the role that patients have in solving the problem of tumor resistance and spotl...
The Melanoma Research Foundation (MRF) met on November 15, 2010 with high-level officials at the Food and Drug Administration (FDA), including Dr. Richard Pazdur, the Direc...
Over the weekend the melanoma community lost a true fighter. Jenna Bockmiller of California died at the age of 20, after a 6-year battle with melanoma. Her tenacious ...
WASHINGTON— With growing financial and time pressures in medical care, the era of the leisurely doctor’s visit is largely gone. As visits become increasin...
Roche announced results from a Phase II clinical study of RG7204 (PLX4032), an inhibitor targeting the BRAF protein that is found in half of metastatic melanoma tumors.&nbs...
The U.S Food and Drug Administration (FDA) extended its deadline for an approval decision on Bristol-Myers Squibb’s (BMS) drug for advanced melanoma, ipilimumab. ...
WASHINGTON, D.C.— For years, treatment options for patients with advanced melanoma have been bleak, with survival averaging around one year after diagnosis. But...
Jul 15, 2025 ET
